Japanese pharmaceutical firm Eisai has launched Leqembi in India, marking the arrival of the nation's first disease-modifying therapy for early Alzheimer’s. The monoclonal antibody targets amyloid-beta plaques to slow cognitive decline in patients with mild impairment.
